

MODULES ON EPILEPSY

MODULE III



Diagnosis and Assessment of Epilepsy

CONTENT

1.	INTRODUCTION	2
2.	DIFFERENTIAL DIAGNOSIS	5
3.	PRINCIPAL EPILEPSY SYNDROMES	8
4.	SPECIAL ISSUES IN EPILEPSY MANAGEMENT	13
5.	EPILEPSY RISK ASSESMENT AND PATIENT-CENTERED CARE	15
6.	REFERENCES	18

INTRODUCTION

Epilepsy and stroke are the two most common neurological disorders. Approximately 7 in 1000 people in the general population have epilepsy at any given time. Epilepsy often begins in childhood, which can affect education, employment, social relationships, and self-esteem. Prompt and accurate diagnosis with appropriate social and medical management is crucial. A family physician, in collaboration with a neurologist, can determine if episodes are epileptic seizures and identify the specific epileptic syndrome.

A strong partnership between family physicians and neurologists enhances the recognition and management of epileptic disorders. As the role of family physicians in epilepsy care grows, the principles outlined in this article will become increasingly important.

DIFFERENTIAL DIAGNOSES

Before determining whether paroxysmal events represent an epileptic disorder, two alternatives must be considered: (a) nonepileptic events mimicking epileptic seizures (Table 1) and (b) true epileptic seizures caused by a nonneurological condition (Box 1). Three conditions commonly imitate epilepsy: syncope, excessive daytime sleep, and pseudoseizures.

Box 1: Conditions that can cause a single seizure or transient epileptic disorder

- Febrile seizure in early childhood
- Sleep deprivation
- Hypoglycemia
- Hyponatremia
- Metabolic encephalopathy
- Central nervous system infection
- Alcohol or drug withdrawal
- Drug abuse (e.g., amphetamines, cocaine)
- Pharmacological agents (e.g., aminophylline, phenothiazines and some analgesics)
- Acute traumatic seizures (mild–moderate head trauma followed immediately by a tonic-clonic seizure)

Table 2 lists several distinguishing manifestations of syncope, which resembles a generalized tonic-clonic (GTC) seizure in the middle of the attack but not at its onset or termination. Typically, while in an erect sitting or standing position, the patient feels faint, vision may blur, the face becomes pale, sweating may occur, and the patient falls atonically with occasional bilaterally synchronous tonic or myoclonic phenomena followed by rapid recovery, albeit with fatigue. The principal differential diagnosis is a treatable cardiac arrhythmia, which should be strongly suspected if syncope-like attacks occur in other circumstances, particularly during exercise.

Excessive daytime sleep, such as episodes of microsleep, occurs in children at school and in adults. It superficially resembles temporal lobe seizures or absence attacks. The patient stares without specific warning or appears inattentive; automatisms may occur. Unlike seizures, episodes of microsleep can be reliably and instantly aborted with an afferent stimulus. Evidence of sleep deprivation includes less than 7 hours of sleep, hypnic jerks during drowsiness, frequent dreaming, prominent snoring, morning arousal only with stimuli, morning irritability, excessive caffeine intake, and prolonged sleeping on weekends.

Psychogenic nonepileptic events are defined as "a paroxysmal behavioral pattern mimicking epileptic seizures and initiated by psychological mechanisms." Diagnosis depends principally on symptomatology (Table 2). A physician should suspect such events in any patient with an apparently intractable cryptogenic "seizure disorder," except in infants or elderly people. Psychogenic events may mimic any type of epileptic seizure and may occur as pseudostatus epilepticus. Distinguishing between psychogenic and frontal lobe epileptic seizures may be difficult, although the latter are shorter and occur principally at night. Psychogenic events may supervene in some truly epileptic patients. Electroencephalogram (EEG) monitoring may be required; however, epileptic seizures that arise from mesial or inferior cortical surfaces may demonstrate no interictal or ictal EEG abnormality.

Table 1: Seizure-like phenomena and possible interpretations

False seizure interpretation	Seizure-like events
Temporal	Daytime microsleep, narcolepsy, night terrors, panic attacks, fugue states, transient global amnesia, pseudoseizures, hyperventilation
Focal sensory	TIAs, hyperventilation
Focal motor	Pseudoseizures, TIAs, movement disorders
Occipital	Migraine
Absence	Daytime microsleep
Atonic	Syncope, cardiac arrhythmias, cataplexy, TIAs, hyperventilation
Myoclonic	Syncope, cardiac arrhythmias
Generalized	Pseudoseizures, syncope, hyperventilation

Note: TIAs = transient ischemic attacks.

At the Epilepsy Programme in London, Ontario, we have developed a system for identifying suspected psychogenic attacks. This consists of taking a detailed description of the attack, 24-hour telemetered EEG recordings over 2–3 days, and a clinical psychological consultation including the Minnesota Multiphasic Personality Inventory-2 (MMPI-2). The MMPI-2 contains profiles of significant sensitivity and specificity for anxiety, somatization, and hysteria, components that predispose a person to pseudoseizures. The evaluation concludes with an interview with the patient, one or more close relatives, the clinical psychologist, and the neurologist.

An erroneous diagnosis of epilepsy carries serious consequences. Missing a cardiac arrhythmia could be fatal. The patient could be unnecessarily exposed to the side effects of antiepileptic medications, especially in emergent situations with pseudostatus epilepticus. Potentially treatable psychiatric conditions could be overlooked. The patient could unnecessarily lose his or her driver's license and occupation.¹

Table 2: Differentiation of generalized tonic-clonic seizures from pseudoseizures and syncope			
Characteristic	Generalized tonic-clonic seizure	Pseudoseizure	Syncope
Circumstances			
Situation	Awake or asleep	Awake	Usually upright; any position if cardiogenic
Precipitating factors	Sleep loss, alcohol withdrawal, flashing lights	Emotion	Emotion, injury, heat, crowds; none if cardiogenic
Presence of others	Variable	Usual	Variable
Motor phenomena			
Vocalization	At onset, if any	During course	None
Location of motor component (if present)	Proximal limb	Proximal limb	None
Generalized motor	Tonic, then clonic	Tonic; flailing; struggling or thrashing, or both	Usually atonic; if syncope lasts > 20 seconds: tonic, then clonic
Tonic posture	Partial flexion or straight	Opisthotonic	–
Head movements	To one side or none	Side to side	–
Clonus/limb jerks	Bilaterally synchronous	Asynchronous	Bilaterally synchronous
Purposeful movements	Absent	Occasional, including avoidance	Absent
Biting	Tongue, inside mouth	Lips, arms, other people	Tongue biting rare
Babinski's sign	Present	Absent	Absent
Autonomic features			
Micturition	Frequent	Rare	Occasional
Eyes	Open	Closed	Open
Pupils	Dilated or hippus during attacks	Normal	Dilated
Colour	Cyanotic or grey	Rubor or normal	Pale
Pulse	Rapid, strong	Normal	Slow if vasovagal, weak if vasodepressor; that of arrhythmias if cardiogenic
Cognitive and behavioural aspects			
Awareness	Lost	Preserved	Lost or impaired
Talking	None	Occasional	None
Restraint necessary	To prevent injury; 1 person suffices	To control violence; many people required	Never
Timing			
Usual duration	1–5 min	5–60 min	1–2 min
Onset	Sudden	Gradual	Gradual; possibly sudden if cardiogenic
Sequence of symptoms	Stereotyped	Variable	Stereotyped
Termination	Spontaneous	Spontaneous or induced by supra-orbital pressure, suggestion	Rapid
Sequelae			
Injury	Frequent, mild; scalp, face, common	Rare, but multiple bruises possible; scalp, face, rare	If sudden onset
Postictal	Tired, confused, sleeps	Alert, emotional outburst	Regains consciousness in 2–3 min; alert but tired

PRINCIPAL EPILEPSY SYNDROMES

Epilepsy Management: Identification and Management of Common Syndromes

The first step in managing epilepsy is identifying the specific syndrome. A syndrome is a constellation of factors that defines each epileptic disorder and influences its management. Determining the syndrome hinges on seizure description and frequency, age at onset, neurological history and functional inquiry, neurological examination, and one or more EEGs. The neurological functional inquiry (review of systems) seeks areas of cognitive and other neurological dysfunctions that may lead to syndrome identification. Neuroimaging may aid in evaluation, but most syndromes are defined by the aforementioned means. Most epileptic disorders that a general physician will see are manifestations of a syndrome. The following describes the most common ones.

Absence Seizures

Absence seizures begin in childhood or early adolescence, with 5–20-second episodes of sudden arrest of activity, staring straight ahead or upward, occasionally with myoclonic activity of the eyelids, face, or upper extremities, and ending abruptly without postictal confusion. Generalized tonic-clonic (GTC; "grand mal") seizures occur in about one-third of such patients, usually in adolescence. Findings from the neurological functional inquiry and examination, including cognition, are normal. Prognosis varies such that "growing out of it" cannot be assured.

Management:

The EEG shows sudden bursts of bilaterally synchronous 3-Hz spike-waves, whose quantity usually reflects the frequency of absence seizures. Complete eradication of absence attacks may require excess medication, necessitating a compromise between adequate dosage and attack frequency. Valproate and lamotrigine act against absence and GTC seizures, whereas ethosuximide, although equally effective, only acts against absence seizures (Table 3).^{2,3,4,5,6,7,8,9,10}

Juvenile Myoclonic Epilepsy and Generalized Tonic-Clonic Seizures upon Awakening

These adolescents usually present with a history of GTC seizures in sleep, within 1 hour of awakening, or late in the evening. Anxiety, sleep loss, and alcohol ingestion are precipitants. Absence attacks occur in about 30% of such patients. Myoclonus of the arms may occur shortly after awakening or in the evening. The history of myoclonus is often difficult to obtain, leaving one with a diagnosis of GTC seizures on awakening.¹¹ Otherwise, the syndromes are identical.

Management:

The EEGs may show 3–4-Hz bisynchronous spike-waves but may be normal. Treatment options include (a) none, if precipitants can be avoided, (b) valproate, the most effective, (c) lamotrigine, if valproate causes side effects, or (d) phenytoin, at a low dose (e.g., about 200 mg/d) (Table 3).

Benign Focal Epilepsy of Childhood with "Rolandic Spikes"

This benign focal epilepsy has no identifiable brain lesion. It accounts for 10%–16% of all patients with seizures under the age of 15 years and is 3–4 times more common than childhood absence seizures.^{12,13} An otherwise healthy child has episodes of a unilateral unusual sensation in the mouth, face, or one arm, with hypersalivation. Focal tonic or clonic phenomena involving the mouth, tongue, or arm may occur, and speech may arrest. Most of such attacks begin during sleep, awakening the patient. This syndrome may present as nocturnal GTC seizure followed by a brief Todd's paresis and may be the most common cause of an idiopathic nocturnal GTC seizure in children between 5 and 10 years of age.

Management:

This benign syndrome cannot be diagnosed without demonstration of typical "rolandic" spikes on an EEG of a nonsedated patient, whether awake or asleep, but 2 EEGs may be required to disclose their presence. Lack of such spikes draws into question this diagnosis and may prompt further evaluation, including imaging. The seizure tendency ends by adolescence in 98% of cases, allowing medication to be omitted. No treatment may be necessary if seizures occur rarely and do not disrupt the child's activities. Alternatively, a low dose of carbamazepine, lamotrigine, valproate, or phenytoin will often suffice.

Temporal Lobe Seizures

The temporal lobe is the most common site of focal seizures, and the seizures most often begin in childhood or adolescence. Auras include an epigastric sensation, fear, and various types of visual, olfactory, or auditory experiential phenomena. Cognition may be impaired during the seizure, manifesting as confusion, a receptive or expressive dysphasia, apraxia, distraction by an experiential phenomenon, or amnesia. Thus, the term "dyscognitive" will replace "complex partial" for this seizure type.

Unilateral or bilateral manual automatisms may occur when cognition is impaired. Dystonic posturing should be sought by observation or history-taking, as it almost always occurs in the arm contralateral to seizure origin. Chewing and swallowing may occur. Ictal speech, even if nonsensical, suggests involvement of the temporal lobe nondominant for language. A GTC seizure may evolve immediately from a dyscognitive one and is often heralded by contralateral head and eye deviation. Alternatively, GTC seizures may appear independently.

Management:

Temporal lobe interictal EEG spikes should be sought to confirm the clinical diagnosis, but more than one EEG may be required. The lack of temporal lobe epileptiform activity on about 3 routine EEGs suggests the need to reassess the diagnosis. MRI scanning is warranted to determine the side and nature of the abnormality and its cause. Generally favored medications include carbamazepine, phenytoin, lamotrigine, and topiramate.¹⁴ However, temporal lobe epilepsy may not respond adequately to antiepileptic drugs. The need to use a second medication, either as monotherapy or dual therapy, reflects the severity of the disorder, reducing the chances of achieving adequate control. In such cases, epilepsy surgery should be considered.

Table 3: Some aspects of principal antiepileptic drugs			
Drug*; side effect	Incidence	Avoidance	Management
Carbamazepine (focal and generalized seizures)			
Rash, maculopapular	5%	Introduce drug slowly	Transient dose reduction
Stevens–Johnson syndrome	Very rare (case reports only)	Introduce drug slowly	Admit to hospital; stop drug
Interaction with other antiepileptic drugs	Common, variable	–	Possible dosage adjustments
Transient leukopenia	10%–20%	–	Complete blood count every 3–6 mo in first year
Persistent leukopenia	2%	–	Complete blood count at intervals or change drug
Aplastic anemia	1 in 200 000	–	Stop drug
Lamotrigine (focal and generalized seizures, including absence seizures)			
Rash, mild	3%–5%	Introduce drug very slowly	Dose reduction
Rash, severe	0.1% in adults, 1%–2% in children	Introduce drug very slowly	Admit to hospital; stop drug
Diplopia	Dose dependent	–	Dose reduction
Phenytoin (Dilantin) (focal and generalized seizures)			
Augments metabolism of oral contraceptives, anticoagulants, other antiepileptic drugs and dexamethasone	Common	–	Dosage adjustment of affected medications
Rash	5%	–	Reduce dose or stop drug
Gingival hypertrophy	25%	Meticulous dental hygiene	Dosage adjustment
Mild hirsutism	75%	–	Stop drug if female patient
Topiramate (focal and generalized seizures)			
Weight loss	10%	–	Reassure patient as levels out; reduce dose
Mental sluggishness	Dose dependent	–	Dose reduction
Fatigue	Dose dependent	–	Dose reduction
Kidney stones	1%–2%	–	Stop drug
Glaucoma	Very rare (case reports only)	–	Stop drug
Valproate (focal and generalized seizures, including absence seizures)			
Weight gain	40%–100%	Exercise	Dose reduction
Hair loss	1%–3%	–	None (side effect usually transient)
Liver failure	0.16% in children < 3 yr; lower in older patients	–	Stop drug
Ethosuximide (absence seizures only)			
Gastrointestinal irritability	20%–33%, usually transient	–	Dose reduction
Depression, psychosis, leukopenia	Very rare (case reports only)	–	Reduce dose or stop drug

*Cost per 100 tablets: Tegretol \$34, lamotrigine \$146, phenytoin \$10, topiramate \$219, Epival \$87, ethosuximide \$31.

Sources: References 2–10. This table was adapted, with permission, from Blume WT: Diagnosis and management of epilepsy. *Can J Contin Med Educ* 2001;12(9):162–3.

SPECIAL ISSUES IN EPILEPSY MANAGEMENT

The First Seizure

Management of a first epileptic seizure depends primarily on clinical analysis and EEG findings. Imaging may be required for (a) seizures not associated with a benign syndrome, (b) focal seizures, (c) non-precipitated attacks, (d) an associated central nervous system disorder, and (e) subsequent unexpectedly refractory seizures.

Avoidable Precipitants:

Sleep loss, stress, and alcohol withdrawal may provoke GTC seizures.¹⁵ Only about 3% of patients with such “stress-induced” attacks will develop spontaneous seizures.

Risk of Brain Tumor:

About 8% of patients with a first seizure may have a brain tumor, dropping to 1% among patients with a normal neurological functional inquiry. This further drops to 0.6% if the findings on neurological examination are normal, and to 0.3% if the EEG shows no focal abnormality.

Recurrence Risk:

In both adults and children, focal seizures, abnormal findings on neurological examination, pre-existing neurological disorder, and focal spikes or generalized spike-waves on EEG increase the risk of recurrence from about 33% to at least 50%.^{17,18,19}

Although antiepileptic drugs reduce the risk of early seizure recurrence, their early use does not apparently affect longer-term remission rates.^{20,21} Moreover, compliance with antiepileptic drug therapy after a single seizure varies among patients.

Women's Issues

Catamenial Epilepsy:

Catamenial epilepsy refers to the appearance or worsening of seizures in the perimenstrual period or, rarely, in the entire second half of the menstrual period if no progesterone is secreted (“inadequate luteal phase” syndrome).²² This relates to a shift of the ratio between estrogen (pro-epileptogenic) and progesterone (anti-epileptogenic). Serum levels of antiepileptic drugs may drop perimenstrually, requiring a slight dose increase.

Contraception:

Enzyme-inducing drugs such as carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, and topiramate may accelerate the metabolism of both estrogen and progesterone, thereby reducing their concentrations by up to 50%. This increases the risk of pregnancy in patients taking oral contraceptives²³ and suggests the need to increase the dose of estradiol from 35 µg to 50 µg if an enzyme-inducing antiepileptic drug is given. Midcycle bleeding may indicate that estrogen levels are too low to block ovulation. Drugs that do not increase the risk of oral contraceptive failure include valproate, lamotrigine, and gabapentin. Oral contraceptives do not impair seizure control.

Pregnancy:

Management considerations derive from two fundamental questions: Do seizures or antiepileptic drugs harm the fetus?

- A prolonged GTC seizure may produce fetal distress or death.²⁴ However, nonconvulsive seizures are apparently innocuous.²⁵ There is no evidence that seizures create deformities. Seizures remain unchanged in 60%, increase in 30%, and decrease in 10% of pregnancies.²³ Poor preconception seizure control predicts incomplete control in pregnancy.

- In preparing a patient with an apparent seizure disorder for pregnancy, the treating physician should ask: Are the events epileptic seizures? Does the epilepsy still require treatment? Can any polytherapy be changed to monotherapy?

Antiepileptic medication levels may decline during pregnancy due to increases in drug metabolism, excretion, and volume of distribution, and decreases in absorption, protein binding, and compliance. It is prudent to measure antiepileptic serum levels before conception, at the beginning of each trimester, and during the last month in patients with moderately severe seizure disorders.

Teratogenic Effects:

The risk of major malformations in babies of mothers taking antiepileptic drugs is about 4%–8% compared to a baseline of 1%–3%.²⁵ Most of this increased risk can be attributed to unfavorable lifestyle, inadequate nutrition, high antiepileptic drug levels, and polypharmacy.^{24,25} Therefore, if possible, change gradually to monotherapy, which is usually a safe procedure.

As no single antiepileptic drug has been shown to be more teratogenic than another, a pregnant woman should continue taking her current drug, which is presumably the best antiepileptic drug for her epilepsy. Barbiturates, phenytoin, and ethosuximide have been associated with congenital heart, cleft lip, and palate abnormalities.²⁴ Valproate and carbamazepine may produce neural tube defects and hydrocephalus, with an incidence of neural tube defects of 1%–2% for valproate and 0.5%–1% for carbamazepine.^{24,25} The effects of oxcarbazepine, topiramate, and lamotrigine are unknown.

Minor malformations such as hypertelorism, low-set ears, and nail-bed hypoplasia may occur, but these usually do not cause serious medical or cosmetic effects.²³

Adequate nutrition and folic acid supplementation by about 4–5 mg/d in any sexually active woman of childbearing age lowers the risk of major fetal malformations, especially neural tube defects, in babies of young women taking antiepileptic drugs.^{23,24,26} As neural tube and cardiac malformations occur during the first 5 weeks of pregnancy, adequate folic acid levels should be established before conception.

Because of high fetal demand, folic acid levels decline in pregnancy, reaching a nadir at term.²³ Women who smoke have lower folic acid levels than those who do not smoke. High folic acid levels do not appear to exacerbate a seizure disorder.

An expert obstetric opinion is needed to monitor for congenital defects. This may involve α -fetoprotein screening: that of amniotic fluid is apparently more reliable than that of maternal serum.²⁴ Ultrasonography at 16–18 weeks' gestation may be necessary as well.

prevented with 10–20 mg per day of vitamin K orally in the last month of pregnancy^{23,25} (Dr. Renato Natale, Associate Chief, St. Joseph's Health Centre and London Health Sciences Centre — University Campus, London, Ont.: personal communication, 2002). Oral vitamin K can be obtained in Canada through the Special Access Programme.^{27,28}

Postpartum Considerations:

Although antiepileptic drugs are detectable in breast milk, their concentrations are usually lower than those in maternal serum. Breast-feeding should not be discouraged in women with epilepsy, because its advantages appear to outweigh the rare (5%–10%) adverse effects to the baby of sedation, hypotonia, and feeding difficulty. Drug withdrawal symptoms have been reported sporadically.²³ Antiepileptic drug levels may gradually increase over the first few weeks after birth as enzymatic induction will have decreased. Mothers with incompletely controlled seizures should avoid bathing an infant in the bathtub without another person present and should change the infant on the floor.

Table 4: Guidelines for determining a patient's fitness to drive

Seizures	Private drivers*
Single, unprovoked seizure before a diagnosis	<ul style="list-style-type: none">• Not drive for at least 3 mo and• Get neurological assessment, including EEG and CT scan
After epilepsy diagnosis	Drive if: <ul style="list-style-type: none">• 12 months seizure free on medication† and• Physician has insight into patient compliance• Physician caution against fatigue, alcohol
After surgery to prevent epileptic seizure	<ul style="list-style-type: none">• Resume driving if 12 months seizure free after surgery†
Seizures in sleep or immediately upon awakening	<ul style="list-style-type: none">• Drive if seizures only occur in sleep or upon awakening for at least 5 years (can reduce period if neurologist agrees)
Medication withdrawal or change	
(a) Initial withdrawal or change	<ul style="list-style-type: none">• Not drive for a period of 3 months from the time medication has been discontinued or changed
(b) If seizures recur after withdrawal or change	<ul style="list-style-type: none">• Resume driving if take medication according to the physician's instructions and• Seizure free for 6 months (can reduce period if neurologist agrees)
(c) Long-term withdrawal and discontinuation of medication	<ul style="list-style-type: none">• Drive any vehicle if seizure free off medication for 5 years
Auras (simple partial seizures)	Drive if <ul style="list-style-type: none">• No impairment in level of consciousness or cognition• Seizures are unchanged for more than 12 months• Neurologist approves
Alcohol-withdrawal induced seizures	Drive if <ul style="list-style-type: none">• Remain alcohol free and seizure free for 12 months• completed a recognized rehabilitation program for substance dependence
Febrile or toxic convulsion	<ul style="list-style-type: none">• No concern if fully recovered from illness
Syncope, sudden falls	<ul style="list-style-type: none">• Single, fully explained event: careful observation only• Multiple, unexplained events: not drive until explained, corrected

Note: EEG = electroencephalogram, CT = computed tomography.

*A private driver is one who drives less than 36 000 km a year or spends less than 720 hours a year behind the wheel, drives a vehicle weighing less than 11 000 kg and does not earn a living by driving. For guidelines pertaining to professional drivers with seizures, refer to reference 30.

†Most private drivers with epilepsy resume driving after being seizure free for 12 months (irrespective of the treatment modality). This 12-month period may be reduced to 6 months on the recommendation of a neurologist.

Source: *Determining medical fitness to drive: a guide for physicians.*³³

Epilepsy in Elderly Patients

The incidence and prevalence of epilepsy increase in elderly people because hemorrhagic and ischemic stroke, primary or secondary tumors, trauma, dementia, and metabolic disorders occur commonly in this population. Fortunately, such epilepsy is seldom intractable. The consequences of uncontrolled seizures may be greater in elderly patients: a fall may fracture a hip or create a subdural hematoma, whereas a GTC seizure may crush a vertebra, causing back pain. A postictal state may manifest as memory loss, cognitive impairment, or an increase in hemiparesis or dysphasia.

The principal differential diagnoses are syncope, sudden falls of elderly people, transient ischemic attacks, or even sleep disturbances. Nonconvulsive status epilepticus appears more often in elderly people, manifesting as mild confusion and forgetfulness or total unresponsiveness for hours or days.

Management:

Diagnostic tests include EEG, CT scanning, and metabolic studies. The need for antiepileptic drugs and ongoing medication should be reviewed to diminish polypharmacy and its complications. The choice of any needed antiepileptic drug is guided by efficacy, ease of introduction and administration, potential drug interactions, and likelihood of significant side effects. As most seizure disorders in elderly patients are focal with possible secondary generalization, carbamazepine and phenytoin are appropriate drugs.^{14,29}

EPILEPSY RISK MANAGEMENT AND PATIENT-CENTERED CARE

Holistic Approach: Healthcare professionals face the challenge of improving both the longevity and quality of life for people with epilepsy, considering medical, environmental, psychological, and social factors.

Daily Risks: Everyday activities, such as bathing, can be potentially fatal for individuals with epilepsy. Issues like employment challenges, social isolation, and stigma are well documented.

Unpredictability of Seizures: Seizure recurrence is unpredictable, posing ongoing risks for people with epilepsy. Accurate diagnosis and treatment are essential, but assessing risk must consider the individual's entire life.

Lack of Standardized Tools: No single widely adopted tool exists for standardized risk assessment in epilepsy.

Patient-Centered Care: This approach shifts patients from being passive recipients to active participants in their healthcare. Self-management and active involvement lead to informed decisions, better psychological adjustment, improved outcomes, feelings of empowerment and control, and enhanced quality of life.

Existing Tools:

SUDEP and Seizure Safety Checklist/Epilepsy Self-Monitor (EpSMon): Allows monitoring of epilepsy and risk assessment while providing education.

- Epilepsy Self-Management Scale: Assesses self-management practices.
- Chalfont Seizure Severity Scale: Evaluates seizure severity.
- Quality of Life in Epilepsy Scale (QOLIE-10): Measures quality of life.

Epilepsy Risk Awareness (ERA) Scale:

Purpose: To fill the gap in comprehensive risk assessment, balancing protection from risks and avoiding undue restrictions to improve quality of life.

Development: Involved iterative design and feedback from patients and healthcare professionals.

Usage: Can be used by all people with epilepsy and healthcare professionals to assess both immediate risk and longitudinal changes for clinical and research purposes.

Function: Facilitates structured, tailored, and sensitive conversations, including mental health support, and aids in creating comprehensive written epilepsy care plans as recommended by NICE.

Research on ERA Scale:

Participants: 102 adults with epilepsy from the Royal Free London NHS Foundation Trust.

Measure: ERA Scale version 2, consisting of four parts, including general information, seizure severity, main risk assessment, and self-management.

Procedure: Participants completed the questionnaire in person, over the phone, or online. A test-retest reliability study was conducted.

Data Analysis: Quantitative analysis used intraclass correlation coefficient (ICC) estimates, and qualitative analysis employed thematic analysis of participant feedback.

Results:

Demographics: Participants aged 18 to 81 years, with a median age of 43.

ICC Estimates: Ranged from 0.330 to 0.889, indicating varying levels of reliability.

Participant Feedback: Highlighted the ERA Scale as a helpful tool but noted the need for more flexible response options and recognition of the complexity of epilepsy.

Modifications:

Response Options: Expanded to include "sometimes" to accommodate variations in epilepsy experiences.

Question Revisions: Based on ICC reliability and participant feedback, some questions were amended, removed, or added.

Final Review: Conducted with 32 participants, leading to a reduction in completion time from 20 to 7 minutes.

Holistic Care: Engaging with patients beyond medical symptoms to consider the impact of epilepsy on their entire lives.

Therapeutic Benefits: Listening to patients provides powerful therapeutic benefits and supports the shift to patient-centered care.

Conclusions: The ERA Scale (version 3) facilitates holistic, tailored conversations between people with epilepsy and healthcare professionals, encouraging shared decision-making to improve quality of life. [33]

REFERENCES

1. Kuyk J, Leijten F, Meinardi H, Spinhoven, Van Dyck R. The diagnosis of psychogenic non-epileptic seizures: a review. *Seizure* 1997;6:243-53.
2. Canadian Pharmacists Association. Tegretol. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. 1666-8.
3. Canadian Pharmacists Association. Lamictal. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. 866-70.
4. Canadian Pharmacists Association. Dilantin. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. 509-12.
5. Canadian Pharmacists Association. Topamax. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. 1709-13.
6. Canadian Pharmacists Association. Epival. Compendium of Pharmaceuticals and Specialties. Ottawa: The Association; 2002. p. 582-6.
7. Canadian Pharmacists Association. Zarontin. Compendium of Pharmaceuticals and Specialties. Ottawa: The Association; 2002. p. 1899.
8. Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK. Antiepileptic drugs. 3rd ed. New York: Raven Press; 1989.
9. Levy RH, Mattson RH, Meldrum BS. Antiepileptic drugs. 4th ed. New York: Raven Press; 1995.
10. Wyllie E. The treatment of epilepsy, principles & practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
11. Blume WT. Epilepsy with generalised tonic-clonic seizures on awakening and other idiopathic generalised epilepsies. In: Meinardi H, editor. The epilepsies, Part II. Vol 73(29) of Handbook of clinical neurology series. Amsterdam: Elsevier Science; 2000. p. 175-82.
12. Van Huffelen AC, van der Meij W. Idiopathic partial epilepsies. In: Meinardi H, editor. The epilepsies, Part II. Vol 73(29) of Handbook of clinical neurology series. Amsterdam: Elsevier Science; 2000. p. 5-35.
13. Loiseau P. Idiopathic and benign partial epilepsies. In: Wyllie E, editor. The treatment of epilepsy. Principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 475-84.

14. Karceski S, Morrell M, Carpenter D. The expert consensus guideline series. Treatment of epilepsy. *Epilepsy Behav* 2001;(Suppl 2):A1-50.
15. Friis ML, Lund M. Stress convulsions. *Arch Neurol* 1974;31:155-9.
16. Bardy AH. Decisions after first seizure. *Acta Neurol Scand* 1991;83:294-6.
17. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. *Neurology* 1991;41:965-72.
18. Shinnar S, Berg AT, Moshe SL, Petix M, Maytal J, Kang H, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study. *Pediatrics* 1990;85:1076-85.
19. Camfield PR, Camfield CS, Dooley JM, Tibbles JA, Fung T, Garner B. Epilepsy after a first unprovoked seizure in childhood. *Neurology* 1985;35:1657-60.
20. Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. *Neurology* 1996;46:41-4.
21. First Seizure Trial Group. Randomized clinical trial on the efficacy of anti-epileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. *Neurology* 1993;43:478-83.
22. Klein P, Herzog AG. Hormones and epilepsy. In: Schmidt D, Schachter SC, editors. *Epilepsy: problem solving in clinical practice*. London: Martin Dunitz; 2000. p. 413-33.
23. Foldvary N. Treatment of epilepsy during pregnancy. In: Wyllie E, editor. *The treatment of epilepsy principles and practice*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 775-86.
24. Lindhout D. Pregnancy and epilepsy. In: Schmidt D, Schachter SC, editors. *Epilepsy: problem solving in clinical practice*. London: Martin Dunitz; 2000. p. 241-52.
25. Sadler RM. Women's issues and epilepsy. Mississauga (ON): The Medicine Group; 2002. Merritt-Putnam Neurology Residents' Course.
26. Canadian Pharmacists Association. Folic acid. *Compendium of pharmaceuticals and specialties*. Ottawa: The Association; 2002. p. 658-9.

27. Canadian Pharmacists Association. Vitamin K. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. 1842-3.
28. Canadian Pharmacists Association. Special Access Programme. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2002. p. A7.
29. Parker BM, Vestal RE. Pharmacokinetics of anticonvulsant drugs in the elderly. In: Wyllie E, editor. The treatment of epilepsy, principles and practice. Philadelphia: Lea & Febiger; 1993. p. 769-74.
30. Canadian Medical Association. Determining medical fitness to drive. 6th ed. Ottawa: The Association; 2000.
31. McLachlan R. Epilepsy and driving. Mississauga (ON): The Medicine Group; 2002. p. 44-7. Merritt-Putnam Neurology Residents' Course.
32. Blume WT. Diagnosis and management of epilepsy. CMAJ. 2003 Feb 18;168(4):441-8. PMID: 12591787; PMCID: PMC143552.
33. Ison, R., Kisan, V., Cole, C., & Angus-Leppan, H. (2020). The Epilepsy Risk Awareness (ERA) Scale: A New Era for Holistic Risk Assessment in Epilepsy. Frontiers in Neurology, 11, 517332

For the use or a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:



Weston Medical Education Foundation of India

Office No:- 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali (East), Mumbai - 400101. M: 9322615653 | W: www.wmefi.co.in